[go: up one dir, main page]

NL301003I2 - Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan Download PDF

Info

Publication number
NL301003I2
NL301003I2 NL301003C NL301003C NL301003I2 NL 301003 I2 NL301003 I2 NL 301003I2 NL 301003 C NL301003 C NL 301003C NL 301003 C NL301003 C NL 301003C NL 301003 I2 NL301003 I2 NL 301003I2
Authority
NL
Netherlands
Prior art keywords
sotagliflozin
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NL301003C
Other languages
English (en)
Other versions
NL301003I1 (nl
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NL301003I1 publication Critical patent/NL301003I1/nl
Publication of NL301003I2 publication Critical patent/NL301003I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06Six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/14Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL301003C 2006-09-29 2019-08-30 Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan NL301003I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84815606P 2006-09-29 2006-09-29
US90571407P 2007-03-08 2007-03-08
US94878007P 2007-07-10 2007-07-10
PCT/US2007/079654 WO2008042688A2 (en) 2006-09-29 2007-09-27 Phlorizin analogs as inhibitors of sodium glucose co-transporter 2

Publications (2)

Publication Number Publication Date
NL301003I1 NL301003I1 (nl) 2019-09-02
NL301003I2 true NL301003I2 (nl) 2019-10-29

Family

ID=38947681

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301003C NL301003I2 (nl) 2006-09-29 2019-08-30 Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan

Country Status (24)

Country Link
US (5) US7781577B2 (nl)
EP (2) EP2308841B1 (nl)
JP (3) JP5283625B2 (nl)
KR (2) KR20150002889A (nl)
AR (1) AR063047A1 (nl)
AT (1) ATE496888T1 (nl)
AU (1) AU2007304971B2 (nl)
BR (1) BRPI0717156B8 (nl)
CA (1) CA2664688C (nl)
DE (1) DE602007012292D1 (nl)
DK (2) DK2308841T3 (nl)
EA (1) EA016511B1 (nl)
ES (1) ES2477216T3 (nl)
FR (1) FR19C1053I2 (nl)
HU (1) HUS1900038I1 (nl)
IL (1) IL197836A (nl)
MX (1) MX2009003305A (nl)
NL (1) NL301003I2 (nl)
NO (1) NO345139B1 (nl)
NZ (1) NZ575811A (nl)
PL (2) PL2308841T3 (nl)
PT (2) PT2308841E (nl)
TW (1) TWI499414B (nl)
WO (1) WO2008042688A2 (nl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体2阻害剤の調製に有用な方法及び化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012025857A1 (en) * 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
CN103596564B (zh) * 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
WO2012172566A2 (en) * 2011-06-13 2012-12-20 Panacea Biotec Ltd. Novel sglt inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013348233C1 (en) * 2012-11-20 2018-09-06 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
RU2648467C2 (ru) 2013-02-04 2018-03-26 Тайсо Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое лекарственное средство для лечения запора
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
KR20240017116A (ko) 2013-12-17 2024-02-06 베링거잉겔하임베트메디카게엠베하 고양이과 동물에서 대사 장애의 치료
MX2016009421A (es) 2014-01-23 2016-09-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales caninos.
EP4454653A3 (en) 2014-04-01 2025-01-22 Boehringer Ingelheim Vetmedica GmbH Treatment of pituitary pars intermedia dysfunction in equine animals
US10555958B2 (en) 2014-09-25 2020-02-11 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
NZ739429A (en) 2015-08-27 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising sglt-2 inhibitors
US10626135B2 (en) * 2016-05-25 2020-04-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
ES2941108T3 (es) 2018-01-05 2023-05-16 Shandong Danhong Pharmaceutical Co Ltd Inhibidor de SGLTS y aplicación del mismo
WO2019166958A1 (en) * 2018-02-28 2019-09-06 Mylan Laboratories Ltd Process for the preparation of sotagliflozin
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
US20210238170A1 (en) * 2018-05-09 2021-08-05 Janssen Pharmaceutica Nv 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JP7425793B2 (ja) 2018-10-29 2024-01-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
PL3873600T3 (pl) 2018-10-29 2024-03-11 Boehringer Ingelheim International Gmbh Pochodne pirydynylosulfonamidu, kompozycje farmaceutyczne i ich zastosowania
US20210038627A1 (en) * 2019-03-01 2021-02-11 Lexicon Pharmaceuticals, Inc. Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
AU2020310274B2 (en) * 2019-07-05 2022-09-29 Shandong Danhong Pharmaceutical Co., Ltd. Crystal form of SGLT inhibitor and application thereof
CA3145678C (en) * 2019-07-26 2022-08-23 Medshine Discovery Inc. Sglt2/dpp4 inhibitor and application thereof
EP4005568B1 (en) 2019-07-26 2024-07-10 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Sglts/dpp4 inhibitor and application thereof
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
CN114727624A (zh) 2019-11-28 2022-07-08 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂在非人哺乳动物的停奶中的用途
EP4106744A1 (en) 2020-02-17 2022-12-28 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
CN111763197A (zh) * 2020-07-08 2020-10-13 青岛大学 一种新型手性吲哚类化合物的合成方法
EP4376830A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2023277704A1 (en) 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240307628A1 (en) 2023-03-06 2024-09-19 Boehringer Ingelheim Vetmedica Gmbh Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
US20240390332A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO1995016049A1 (en) 1993-12-08 1995-06-15 The Scripps Research Institute Catalytic chemo-enzymatic asymmetric synthesis of carbohydrates
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
JP2885191B2 (ja) 1996-07-09 1999-04-19 日本電気株式会社 液晶プロジェクタ
JP3928197B2 (ja) 1997-01-23 2007-06-13 住友化学株式会社 アリール置換芳香族類の製造方法
US6664399B1 (en) 1999-09-02 2003-12-16 E. I. Du Pont De Nemours & Company Triazole linked carbohydrates
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
BR0109323A (pt) 2000-03-17 2002-12-24 Kissei Pharmaceutical Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1385856B1 (en) 2001-04-11 2006-02-22 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
EP1432720A1 (en) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
EP1432721A4 (en) 2001-09-13 2008-02-20 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF
FR2831169B1 (fr) 2001-10-22 2003-12-12 Servier Lab Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7521568B2 (en) 2001-12-14 2009-04-21 Purdue Research Foundation Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof
US6927294B1 (en) * 2002-03-08 2005-08-09 University Of Southern California Nitrogen-containing heterocycles
DE10213228A1 (de) 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
JP3813160B2 (ja) * 2002-08-09 2006-08-23 大正製薬株式会社 アリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845995A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de pyrrolo[3,4-c]carbazole et de pyrido[2,3-b]pyrrolo[3,4-e]indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004050122A1 (ja) 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. 高血糖症に起因する疾患の予防又は治療剤
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7655633B2 (en) 2002-12-25 2010-02-02 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
EP1581543A4 (en) 2003-01-03 2008-03-19 Bristol Myers Squibb Co METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS
US7202350B2 (en) 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004089966A1 (ja) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. 選択的なヘテロアリール 5-チオ-β-D-アルドヘキソピラノシドの製造法
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
AU2004261660A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
EP1680131A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDOLE-O-GLUCOSIDES
RS20060320A (en) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
CA2549022A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
DE502004008951D1 (de) 2003-08-26 2009-03-19 Boehringer Ingelheim Pharma Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2542077A1 (en) 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE102004017793A1 (de) 2004-02-21 2005-09-08 Biofrontera Discovery Gmbh Trioxacarcine und deren Verwendung
CN1922301A (zh) 2004-02-24 2007-02-28 诺和酶股份有限公司 液体去污剂中酶的稳定化
ZA200606792B (en) 2004-03-04 2007-12-27 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
AU2005225511C1 (en) 2004-03-16 2023-04-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
WO2006002233A2 (en) 2004-06-22 2006-01-05 Wall, Michael, A. Alvaradoins e-n, new antitumor and cytotoxic anthracenone g-glycosides
US7393836B2 (en) * 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
KR20070048188A (ko) 2004-07-08 2007-05-08 아스텔라스세이야쿠 가부시키가이샤 아줄렌 유도체의 제조방법 및 이의 합성 중간체
EP1771430A2 (en) 2004-07-08 2007-04-11 Ciba Specialty Chemicals Holding Inc. Preparation of alpha-hydroxy and alpha-amino ketones
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20080045466A1 (en) 2004-07-21 2008-02-21 Kenji Katsuno Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004039096A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004046583A1 (de) 2004-09-23 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006037335A2 (en) 2004-10-06 2006-04-13 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換((ヘテロ)アリールエチニル−ベンジル)−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体2(sglt2)インヒビターとしてのそれらの使用
WO2006104897A2 (en) 2005-03-25 2006-10-05 Inspire Pharmaceuticals, Inc. Cytoskeletal active compounds, composition and use
US20060240496A1 (en) 2005-04-21 2006-10-26 Lakshmi Anne Immunogens, derivatives and immunoassay for ethyl glucuronide
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
US8253752B2 (en) 2006-07-20 2012-08-28 Qualcomm Incorporated Method and apparatus for encoder assisted pre-processing
EP2049524A2 (en) 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
US20080107744A1 (en) * 2006-11-06 2008-05-08 Jack Fa-De Chu Injectable hollow tissue filler
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体2阻害剤の調製に有用な方法及び化合物
US8015005B2 (en) 2008-02-15 2011-09-06 Motorola Mobility, Inc. Method and apparatus for voice searching for stored content using uniterm discovery
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法
AU2013348233C1 (en) * 2012-11-20 2018-09-06 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1

Also Published As

Publication number Publication date
EP2308841B1 (en) 2014-04-16
DK2089361T3 (da) 2011-04-18
US20080113922A1 (en) 2008-05-15
JP5701845B2 (ja) 2015-04-15
IL197836A0 (en) 2009-12-24
IL197836A (en) 2014-01-30
US20140135277A1 (en) 2014-05-15
AU2007304971A1 (en) 2008-04-10
KR20150002889A (ko) 2015-01-07
PL2089361T4 (pl) 2012-09-28
CA2664688C (en) 2015-03-17
CA2664688A1 (en) 2008-04-10
EA016511B1 (ru) 2012-05-30
NO345139B1 (no) 2020-10-12
FR19C1053I2 (fr) 2020-04-03
JP2010504998A (ja) 2010-02-18
EA200970337A1 (ru) 2009-08-28
WO2008042688A3 (en) 2008-06-12
KR101492277B1 (ko) 2015-02-11
BRPI0717156B8 (pt) 2021-05-25
ATE496888T1 (de) 2011-02-15
US8476413B2 (en) 2013-07-02
EP2308841A2 (en) 2011-04-13
US7781577B2 (en) 2010-08-24
PL2308841T3 (pl) 2014-09-30
NO20091700L (no) 2009-06-16
JP5283625B2 (ja) 2013-09-04
EP2089361B1 (en) 2011-01-26
TW200826929A (en) 2008-07-01
DE602007012292D1 (de) 2011-03-10
US9365602B2 (en) 2016-06-14
TWI499414B (zh) 2015-09-11
NL301003I1 (nl) 2019-09-02
JP2013079243A (ja) 2013-05-02
US20170087172A1 (en) 2017-03-30
EP2308841A3 (en) 2011-10-26
KR20090061072A (ko) 2009-06-15
JP2015120736A (ja) 2015-07-02
ES2477216T3 (es) 2014-07-16
DK2308841T3 (da) 2014-06-30
MX2009003305A (es) 2009-05-28
PT2089361E (pt) 2011-05-02
US20190099436A1 (en) 2019-04-04
EP2089361A2 (en) 2009-08-19
AU2007304971B2 (en) 2013-06-20
WO2008042688A2 (en) 2008-04-10
US20100311673A1 (en) 2010-12-09
NZ575811A (en) 2011-10-28
HUS1900038I1 (hu) 2019-09-30
PT2308841E (pt) 2014-06-11
BRPI0717156A2 (pt) 2013-10-15
DK2089361T5 (da) 2012-01-16
PL2089361T3 (pl) 2011-06-30
AR063047A1 (es) 2008-12-23
FR19C1053I1 (fr) 2019-11-15
BRPI0717156B1 (pt) 2020-06-30
JP5889453B2 (ja) 2016-03-22

Similar Documents

Publication Publication Date Title
NL301209I1 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl) Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl) Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301305I2 (nl) Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl) cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl) alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301250I2 (nl) piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301304I2 (nl) aprocitentan of een farmaceutisch aanvaardbaar zout daarvan
NL301291I2 (nl) sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl) Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I2 (nl) upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL350108I2 (nl) Isofetamid of een zout daarvan
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NL300865I1 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL300886I2 (nl) baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301284I2 (nl) Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
FIC20190029I1 (fi) Brigatinibi tai sen farmaseuttisesti hyväksyttävä suola
NL301065I2 (nl) Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NO2017059I1 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav